Abstract
Objective. To study the efficacy of courses of i.v., Cytoflavin in combination with the standard rehabilitation program for postcovid syndrome for correction of postcovid asthenia. Materials and methods. Follow-up investigations were carried out in 45 patients with postcovid syndrome at the second stage of rehabilitation. Patients were divided into two groups of comparable sex and age. The volume of lung damage was also similar in both groups, at 25–80%. The 24 patients making up the comparison group received standard postcovid rehabilitation: pulsed magnetotherapy, inhalation therapy, aeroionotherapy, infrared laser therapy, courses of aerobic training, rational psychotherapy, and successive drug therapy. The 21 patients of the study group additionally received intravenous Cytoflavin daily for 10 days. The dynamics of increases in scores on the Rehabilitation Routing Scale, the Hamilton Depression Rating Scale (HDRS), the Asthenic Status Scale, and the 6-minute walk test at admission and discharge were also monitored. Results and conclusions. Addition of courses of intravenous Cytoflavin to the complex rehabilitation program for postcovid syndrome significantly improved the general functional state of the body, decreased levels of depression and asthenization, and increased physical exercise tolerance.
Keywords: new coronavirus infection, COVID-19, rehabilitation, postcovid syndrome, postcovid asthenia, mitochondrial dysfunction
Footnotes
Translated from Zhurnal Nevrologii i Psikhiatrii imeni S. S. Korsakova, Vol. 121, No. 8, Iss. 1, pp. 25–29, August, 2021.
References
- 1.Temporary Methodological Guidelines, Prophylaxis, Diagnosis, and Treatment of the New Coronavirus Infection (COVID-19), Moscow, Vers. 10, Feb. 8, 2021.
- 2.Temporary Methodological Guidelines, Medical Rehabilitation in the New Coronavirus Infection (COVID-19), Moscow, Vers. 2, July 31, 2020.
- 3.K. Holder and P. H. Reddy, “The COVID-19 effect on the immune system and mitochondrial dynamics in diabetes, obesity, and dementia,” Neuroscientist, Online ahead of print, Sept. 26, 2020, 10.1177/1073858420960443. [DOI] [PubMed]
- 4.Fernández-Ayala D, Navas P, López-Lluch G. Age-related mitochondrial dysfunction as a key factor in COVID-19 disease. Exp. Gerontol. 2020;142:111147. doi: 10.1016/j.exger.2020.111147. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Nunn A, Guy G, Brysch W, et al. SARS-CoV-2 and mitochondrial health: implications of lifestyle and ageing. Immun. Ageing. 2020;17(1):33. doi: 10.1186/s12979-020-00204-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Burtscher J, Cappellano G, Omori A, et al. Mitochondria: In the cross fire of SARS-CoV-2 and immunity. iScience. 2020;23(10):101631. doi: 10.1016/j.isci.2020.101631. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Gibellini L, De Biasi S, Paolini A, et al. Altered bioenergetics and mitochondrial dysfunction of monocytes in patients with COVID-19 pneumonia. EMBO Mol. Med. 2020;12(12):e13001. doi: 10.15252/emmm.202013001. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Shenoy S. Coronavirus (Covid-19) sepsis: revisiting mitochondrial dysfunction in pathogenesis, aging, inflammation, and mortality. Inflamm. Res. 2020;69(11):1077–1085. doi: 10.1007/s00011-020-01389-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Gatti P, Ilamathi HS, Todkar K, Germain M. Mitochondria targeted viral replication and survival strategies – Prospective on SARS-CoV-2. Front. Pharmacol. 2020;11:578599. doi: 10.3389/fphar.2020.578599. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Gvozdjakova A, Klauco F, Kucharska J, Sumbalova Z. Is mitochondrial bioenergetics and coenzyme Q10 the target of a virus causing COVID-19? Bratisl. Lek. Listy. 2020;121(11):775–778. doi: 10.4149/BLL_2020_126. [DOI] [PubMed] [Google Scholar]
- 11.E. Wood, K. Hall, and W. Tate, “Role of mitochondria, oxidative stress and the response to antioxidants in myalgic encephalomyelitis/chronic fatigue syndrome: a possible approach to SARS-CoV-2 ‘long-haulers’?” Chronic Dis. Transl. Med., Online ahead of print, Nov. 21, 2020, 10.1016/j.cdtm.2020.11.002. [DOI] [PMC free article] [PubMed]
- 12.Stefano G, Ptacek R, Ptackova H, et al. Selective neuronal mitochondrial targeting in SARS-CoV-2 infection affects cognitive processes to induce ‘brain fog’ and results in behavioral changes that favor viral survival. Med. Sci. Monit. 2021;27:e930886. doi: 10.12659/MSM.930886. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Ouyang L, Gong J. Mitochondrial-targeted ubiquinone: A potential treatment for COVID-19. Med. Hypotheses. 2020;144:110161. doi: 10.1016/j.mehy.2020.110161. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.V. V. Afanas’ev, Cytoflavin in Intensive Care. A Manual for Doctors, St. Petersburg (2005).
- 15.Bul’on VV, Zarubina IV, Kovalenko AL, et al. The cerebroprotective effect of Cytoflavin in closed traumatic brain injury. Eksperim. Klin. Farmakol. 2003;6:46–48. [Google Scholar]
- 16.P. R. Kamchatnov, Chronic Disorders of the Cerebral Circulation, the Possibilities of Metabolic Therapy. A Manual, Moscow (2008).
- 17.E. G. Klocheva, M. V. Aleksandrov, and E. B. Fomina, “The use of Cytoflavin in patients with cerebral hypoxia of ischemic origin,” Vestn. St. Peterb. Gos. Med. Akad. Mechnikova, No. 1–2, 24–30 (2002).
- 18.A. I. Fedin, S. A. Rumyantseva, O. R. Kuznetsov, et al., Antioxidant and Energy-Protective Therapy of Ischemic Stroke. Methodological Guidelines, Moscow (2004).
- 19.A. I. Fedin, S. A. Rumyantseva, and M. A. Piradov, et al., “Efficacy of the neurometabolic protector Cytoflavin in cerebral infarct,” Vestn. St. Peterb. Gos. Med. Akad. Mechnikova, No. 1, 13–19 (2005).
- 20.Fedin AI, Rumyantseva SA, Piradov MA, et al. Clinical efficacy of Cytoflavin in patients with chronic cerebral ischemia (a multicenter placebo-controlled randomized trial) Vrach. 2006;13:52–58. [Google Scholar]
- 21.Zakharov VV, Voznesenskaya TG. In: Neuropsychiatric Disorders. Diagnostic Tests. Yakhno NN, editor. Moscow: MED Press-Inform; 2016. [Google Scholar]